- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Secondary Progress Multiple Sclerosis in Colombia
Total 164 results
-
BiogenTerminatedSecondary Progressive Multiple SclerosisUnited States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland
-
SanofiActive, not recruitingSecondary Progressive Multiple SclerosisUnited States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more
-
Atara BiotherapeuticsTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States, Australia, Canada
-
Novartis PharmaceuticalsCompletedSecondary Progressive Multiple SclerosisChina, Germany, United States, Romania, Italy, Austria, Belgium, Czechia, Spain, Australia, Canada, France, Israel, Switzerland, Bulgaria, Hungary, Netherlands, United Kingdom, Estonia, Latvia, Lithuania, Russian Federation, Turkey, J... and more
-
Genentech, Inc.CompletedMultiple Sclerosis, Primary Progressive | Relapsing Multiple SclerorsisUnited States, Germany, Canada, Sweden
-
Institute for Clinical ResearchUnknownRelapsing-Remitting Multiple SclerosisUnited States
-
University of British ColumbiaGenzyme, a Sanofi CompanyCompletedRelapsing Remitting Multiple SclerosisCanada
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisCanada
-
BiogenTerminatedMultiple Sclerosis, Relapsing-Remitting | Relapsing-Remitting Multiple SclerosisCanada
-
BayerCompletedMultiple SclerosisUnited States, Canada
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisPoland, Hungary, United States, Czech Republic
-
Anokion SAActive, not recruitingRelapsing Remitting Multiple Sclerosis | Multiple Sclerosis (MS)United States
-
Hoffmann-La RocheActive, not recruitingMultiple SclerosisUnited States, Italy, Poland
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
BayerCompletedRelapsing Remitting Multiple Sclerosis (RRMS)China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
-
VA Office of Research and DevelopmentActive, not recruitingMultiple SclerosisUnited States, Canada
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisCroatia, United States, Czech Republic, France, Italy, Mexico, South Africa, United Kingdom, Germany, Poland, Romania, Ukraine, Netherlands, Austria, Canada, Israel, New Zealand, Slovakia, Greece, Serbia, India, Belgium, Switzerland, ... and more
-
Novartis PharmaceuticalsRecruitingRelapsing-Remitting Multiple SclerosisCanada, United States
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedMultiple SclerosisColombia, Panama, Peru, Brazil, Jordan, Malaysia, Mexico, Argentina
-
McGill UniversityNovartisCompletedMultiple Sclerosis-Relapsing-RemittingCanada
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisFinland, Germany, Spain, Belgium, Italy, Canada, France, New Zealand, Israel, Hungary, Greece, Australia, Netherlands, United Kingdom, Denmark, Ireland, Sweden, Poland, Czech Republic, Switzerland, Turkey
-
George Washington UniversityCompletedMultiple Sclerosis, Relapsing-RemittingUnited States
-
Novartis PharmaceuticalsTerminatedRelapsing-remitting Multiple Sclerosis (RRMS)United States, Canada, Mexico, Brazil, Puerto Rico, Argentina, Chile
-
EMD Serono Research & Development Institute, Inc.Terminated
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisFrance, Italy, Spain, Czechia, Hungary, Austria, Belgium, Canada, Portugal, Slovakia, Slovenia
-
Hoffmann-La RochePPDRecruitingRelapsing-Remitting Multiple SclerosisUnited States, Belgium, Canada, Spain, India, Italy, Mexico, Portugal, Argentina, Austria, Brazil, United Kingdom, Germany, Netherlands, Serbia, Australia, Bulgaria, France, Greece, Hungary, Poland, Ukraine, Estonia, Denmark, Croatia, Latvia and more
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
Eicos Sciences, Inc.CompletedRaynaud Phenomenon Secondary to Systemic SclerosisUnited States
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States, France, Germany, Spain, Belgium, Czechia, Switzerland, United Kingdom, Austria, New Zealand, Australia, South Africa, Ukraine, Italy, Slovakia, Greece, Poland, Israel, Netherlands, Bulgaria, Serbia, India, Romania, Estonia and more
-
Hoffmann-La RocheActive, not recruitingProgressive Multiple Sclerosis (PMS)United States, Canada, Brazil, France, Netherlands, Ireland, Germany, Italy, Poland, Russian Federation, Spain, Colombia, Morocco, Hungary, Denmark, Lebanon, Mexico, Costa Rica, Bosnia and Herzegovina, Czechia, Egypt, Guatemala, Panama and more
-
BayerCompletedMultiple Sclerosis | Multiple Sclerosis, Relapsing-RemittingUnited States
-
University of British ColumbiaBayer Healthcare Pharmaceuticals, Inc./Bayer Schering PharmaCompleted
-
BiogenAlkermes, Inc.CompletedRelapsing Remitting Multiple SclerosisUnited States, Germany, Poland
-
University of British ColumbiaTeva Pharmaceuticals USACompleted
-
University of British ColumbiaHoffmann-La RocheUnknown
-
BiogenAbbVieCompletedRelapsing-Remitting Multiple SclerosisSweden, United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Ukraine, Denmark, Finland, Romania, Canada, France, Hungary, Israel, Switzerland, Serbia, India, Mexico, Poland, Georgia, Ireland, Argentin... and more
-
NovartisCompletedEfficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (FREEDOMS)Relapsing-remitting Multiple SclerosisCanada, Australia, Israel, Belgium, Czech Republic, Finland, France, Germany, Greece, Lithuania, Netherlands, Poland, Russian Federation, Slovakia, South Africa, Sweden, Switzerland, Turkey, United Kingdom
-
EMD SeronoMerck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. LtdTerminatedMultiple SclerosisUnited States, Belgium, Canada, Czech Republic, Germany, Japan, Poland, Russian Federation, Spain, Ukraine, Greece
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisBelgium, Germany, Italy, Norway, France, Mexico, Australia, Spain, Portugal, Greece, Netherlands, United Kingdom, Czechia, Slovakia, Finland, Canada, Argentina, Brazil
-
Hoffmann-La RocheActive, not recruitingMultiple Sclerosis (MS)United States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisPoland, Hungary, Turkey, Spain, Germany, United States, Canada, Switzerland, Russian Federation, Norway, Italy, Finland
-
Hoffmann-La RocheActive, not recruitingMultiple Sclerosis, Primary ProgressiveUnited States, Canada, Australia, United Kingdom, Hungary, Bulgaria, Puerto Rico, Poland, Argentina, Brazil, Germany, Greece, Italy, Peru, Portugal, Russian Federation, Spain, Turkey, Ukraine, Israel, France, Switzerland, Colombia, Me... and more
-
BayerCompletedMultiple Sclerosis, Relapsing-RemittingUnited States
-
Ono Pharma USA IncCompletedMultiple SclerosisUnited States, Belgium, Canada, Czech Republic, Germany, Greece, Japan, Poland, Russian Federation, Spain, Ukraine
-
Eicos Sciences, Inc.CompletedRaynaud's Phenomenon Secondary to Systemic SclerosisUnited States
-
BiogenCompletedMultiple SclerosisUnited States, Italy, Hungary, United Kingdom, Spain, France, Australia, Germany, Canada, Switzerland, Argentina, Czech Republic, Croatia